CCN1 and atherosclerosis: Hsu et al. reported that disrupting CCN1-integrin α6β1 interaction by a mutation (defective in binding α6β1) in Ccn1 gene or using an antagonist T1 peptide (derived from an α6β1-binding sequence of CCN1) may serve as a promising therapeutic strategy to prevent or treat atherosclerosis [385].